Literature DB >> 8671621

Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo.

R Tarazona1, A M Sponaas, G Mavria, M Zhou, R Schulz, P Tomlinson, J Antoniou, A L Mellor.   

Abstract

The influence of microenvironment on the course of CD8 + T cell responses in vivo was investigated by injecting H-2Kb-specific T cells from donor TCR transgenic (TCR-Tg) mice into H-2kb-Tg mice. H-2Kb expression in recipients was either ubiquitous (CBK mice) or restricted to myeloid and erythroid cells (K beta mice). Donor T cells proliferated as extensively and acquired similar surface phenotypes in spleen of both recipient types. Thus, neither the restricted pattern of H-2Kb expression nor the significantly reduced level of H-2Kb expression by myeloid cells in Kbeta recipients affects the ability of the splenic microenvironment to prime T cell proliferation in vivo. However, an unsustained burst of cytolytic activity was generated rapidly in spleen of CBK recipients, whereas relatively little cytolytic activity was generated in K beta spleen. This indicates that effector T cells were not generated efficiently in spleen of Kbeta recipients even though extensive T cell proliferation was taking place in this microenvironment. Furthermore, activated donor T cells dispersed rapidly throughout primary and secondary lymphoid organs of Kbeta recipients, whereas few T cells migrated from spleen in CBK recipients. Consequently, the course of CD8+ T cell responses and the anatomical distribution of activated T cells are profoundly influenced by the nature of the antigenic microenvironment encountered in vivo. We conclude that T cells rapidly proliferate and acquire new tissue-homing characteristics but do not differentiate into cytolytic effector cells at the site of priming when they encounter myeloid cells expressing low levels of antigen in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671621     DOI: 10.1093/intimm/8.3.351

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

1.  Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division.

Authors:  Geon Kook Lee; Hyeon Jin Park; Megan Macleod; Phillip Chandler; David H Munn; Andrew L Mellor
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Transplantation tolerance to a single noninherited MHC class I maternal alloantigen studied in a TCR-transgenic mouse model.

Authors:  Yoshinobu Akiyama; Stéphane M Caucheteux; Cécile Vernochet; Yoshiko Iwamoto; Katsunori Tanaka; Colette Kanellopoulos-Langevin; Gilles Benichou
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

3.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

4.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

5.  IDO activates regulatory T cells and blocks their conversion into Th17-like T cells.

Authors:  Babak Baban; Phillip R Chandler; Madhav D Sharma; Jeanene Pihkala; Pandelakis A Koni; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

6.  Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition.

Authors:  Adnan Khan; Hongmei Fu; Lee Aun Tan; Jennifer E Harper; Sven C Beutelspacher; Daniel F P Larkin; Giovanna Lombardi; Myra O McClure; Andrew J T George
Journal:  Eur J Immunol       Date:  2013-01-18       Impact factor: 5.532

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.